Anti-IL-5 monoclonal antibody
Reslizumab
Brand names: Cinqaero
Adult dose
Dose: 3 mg/kg IV every 4 weeks
Route: IV
Frequency: q4w
Clinical pearls
- Severe eosinophilic asthma (eosinophils ≥400/μL) — specialist
- Per NICE TA479
Contraindications
- Hypersensitivity
- Active parasitic infection
- Pregnancy/breastfeeding (caution)
Side effects
- Anaphylaxis (boxed warning)
- Myalgia
- Increased CK
- Pharyngeal/oral pain
Interactions
- Live vaccines
- Helminth co-infection (treat first)
Monitoring
- FEV1
- Eosinophils
- ACQ
Reference: BNF; NICE TA479; BTS/SIGN; https://bnf.nice.org.uk/drugs/reslizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Drugs
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024